Kodiak Sciences
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1200 Page Mill Rd, Palo Alto, California...Phone Number
(650) 281-0850Website
www.kodiak.comRevenue
-Stock Symbol
KODIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Kodiak Sciences
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, nave macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incRead more
Kodiak Sciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kodiak Sciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Kodiak Sciences launches new products
Funding: Get notified immidiatlly once Kodiak Sciences has new funding data
Kodiak Sciences, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Kodiak Sciences is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Kodiak Sciences recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if Kodiak Sciences has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Kodiak Sciences
Click to see if Kodiak Sciences had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Kodiak Sciences as Masked Content
Find 3 more new buyers
Compare Similar Companies to Kodiak Sciences
Compare insights from companies similar to Kodiak Sciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$123.9M
51-200
Public
$547.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Company Profile Activity
Activity Insights
Kodiak Sciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Kodiak Sciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Kodiak Sciences.
Kodiak Sciences financials insights
Gather financial insights about Kodiak Sciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2009
Other Financing Round
$1.8M
2016
Series B
$34M
2018
Debt
$33M
Stock Offering
$90M
2019
Stock Offering
$317.4M
2020
Debt
$150K
Kodiak Sciences Tech Stack
A closer look at the technologies used by Kodiak Sciences
Most Recent Scoops
Person-Based
Stake & Stock Ownership, Finance
Earnings
Kodiak Sciences has reported packaging revenue of approximately $1 billion for the current year, up from $635 million last year and $300 million the year prior, with advanced packaging market share growing from under 1% a few years ago to over 6% last year and an expected mid-7% range this year. KLA has gained over 150 basis points of advanced packaging market share over the last five years and targets an additional 150 basis points over the next five years, consistent with its $26 billion 2030 revenue target model.
Earnings, Forecasting, Finance
Project
Kodiak Sciences has announced that Zenkuda (tarcocimab), its anti-VEGF antibody biopolymer conjugate, is BLA-ready for diabetic retinopathy, retinal vein occlusion, and wet AMD, following four successful pivotal studies with positive top-line data.
Medical Research, Pharmaceuticals
Project
Kodiak Sciences has announced that top-line data from the Phase III DAYBREAK study evaluating Zenkuda (tarcocimab) in wet AMD is expected in late September of this year, with a BLA filing anticipated shortly thereafter.
Clinical Operations
Project
Medical Research, Pharmaceuticals
Kodiak Sciences News & Media
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
Phase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients with diabetic macular edema PALO ALTO, Calif., Aug. 10, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching,...Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026
First pivotal cohort enrolled 300 subjects, with topline clinical data from 24-week primary endpoint on track for December 2026 release Completion of enrollment in the second pivotal cohort evaluating 600 subjects across the PEAK and PINNACLE studies is expected in 4Q 2026, with topline...Kodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should Know
This clinical-stage biotech focused on retinal therapies reported a notable insider sale amid a year of exceptional stock performance.Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
PALO ALTO, Calif., May 28, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that Victor Perlroth, M.D., Chief Executive...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kodiak Sciences
Sign Up For FreeTo access detailed company insights
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat w... Read More
